A5017274704- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Immune cells in cancer
- Extracellular vesicles in disease
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Kruppel-like factors research
- Protease and Inhibitor Mechanisms
- Multiple Myeloma Research and Treatments
- Biochemical Analysis and Sensing Techniques
- Mesenchymal stem cell research
- CAR-T cell therapy research
- Advanced Chemical Sensor Technologies
- Chronic Lymphocytic Leukemia Research
- IL-33, ST2, and ILC Pathways
- RNA Interference and Gene Delivery
- Adenosine and Purinergic Signaling
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Platelet Disorders and Treatments
- Immune Cell Function and Interaction
- Olfactory and Sensory Function Studies
- Autophagy in Disease and Therapy
University of Bologna
2016-2025
University of Cambridge
2017-2024
National Health Service
2017-2024
Istituto di Ematologia di Bologna
2020-2023
NHS Blood and Transplant
2023
Wellcome/MRC Cambridge Stem Cell Institute
2017-2023
Policlinico S.Orsola-Malpighi
2017-2021
Azienda USL di Bologna
2020-2021
Medical Research Council
2017-2019
Like normal hematopoietic stem cells, leukemic cells depend on their bone marrow (BM) microenvironment for survival, but the underlying mechanisms remain largely unknown. We have studied contribution of nestin
NPM1-mutated acute myeloid leukaemia (NPM1mut AML) represents a mostly favourable/intermediate risk disease that benefits from allogeneic haematopoietic stem cell transplantation (HSCT) in case of measurable residual (MRD) relapse or persistence after induction chemotherapy. Although the negative prognostic role pre-HSCT MRD is established, no recommendations are available for management peri-transplant molecular failure (MF). Based on efficacy data venetoclax (VEN)-based treatment NPM1mut...
We and others have shown that the Tissue Inhibitor of Metalloproteinases-1 (TIMP-1), a member inflammatory network exerting pleiotropic effects in bone marrow (BM) microenvironment, regulates survival proliferation different cell types, including normal hematopoietic progenitor cells. Moreover, TIMP-1 has been to be involved cancer progression. However, its role leukemic microenvironment not addressed. Here, we investigated activity on Acute Myelogenous Leukemia (AML) functions. First, found...
Extracellular ATP released from dying cells, including tumor is a key mediator of inflammation and tolerance by binding to purinergic receptors on dendritic resulting in inflammasome activation (via P2X7R), cell maturation P2Y11R), Indoleamine-2,3-dioxygenase 1 upregulation. However, the regulation ATP-driven expression human cells has been poorly investigated. In this work we aimed investigate molecular via provide an in-depth characterization T regulatory induced 1-expressing cells. We...
Myelofibrosis (MF) is a clonal neoplasia associated with chronic inflammation due to aberrant cytokine production. Mutations in Janus Kinase-2 (JAK2), calreticulin (CALR) and myeloproliferative leukemia protein (MPL) genes have been recently MF they all activate the JAK/STAT signaling pathway. Since this pathway essential shaping immune response, we investigated role of circulating subsets cytokines 38 patients (20 carrying JAK2(V617F),13 exon-9 CALR mutation 5 triple negative). In...
Myelofibrosis (MF) is characterized by chronic inflammation and hyper-activation of the JAK-STAT pathway. Infections are one main causes morbidity/mortality. Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, may further increase infectious risk. Monocytes critical players in inflammation/immunity through cytokine production release bioactive extracellular vesicles. However, functional behavior MF monocytes, particularly during RUX therapy, still unclear. In this study, we found that...
Acute myeloid leukemia (AML) is an aggressive heterogeneous disease characterized by several alterations of the immune system prompting progression and treatment response. The therapies available for AML can affect lymphocyte function, limiting efficacy immunotherapy while hindering leukemia-specific reactions. Recently, based on Venetoclax (VEN), a specific B-cell lymphoma 2 (BCL-2) inhibitor, in combination with hypomethylating agents (HMAs) or low-dose cytarabine, has emerged as promising...
Abstract Introduction Due to their immunomodulatory properties, mesenchymal stromal cells (MSCs) have been used for auto-immune disease treatment. Crohn (CD) and ulcerative colitis are two major inflammatory bowel diseases (IBDs), resulting from pathological immune responses environmental or microbial antigens. Preclinical clinical studies suggested that MSC-based cellular therapy hold promising potential IBD However, open issues include the selection of proper cell dose, source optimal...
Myelofibrosis (MF) is a clonal neoplasia of the hemopoietic stem/progenitor cells associated with genetic mutations in Janus kinase 2 (JAK2), myeloproliferative leukemia virus oncogene (MPL), and calreticulin (CALR) genes. MF also characterized by state chronic inflammation. Calreticulin (CRT), as multifunctional protein, involved spectrum cellular processes including inflammation, autoimmunity, cancer initiation/progression. Based on this background, we hypothesised that circulating CRT...
// Daria Sollazzo 1, * , Dorian Forte Nicola Polverelli 1 Marco Romano Margherita Perricone Lara Rossi Emanuela Ottaviani Simona Luatti Giovanni Martinelli Vianelli Michele Cavo Francesca Palandri Lucia Catani Department of Experimental, Diagnostic and Specialty Medicine, Institute Hematology "L. e A. Seràgnoli", University Bologna, Italy These authors contributed equally to this work Correspondence to: Catani, email: lucia.catani@unibo.it Keywords: circulating CD34 + cells, myelofibrosis,...
The contribution of cell-extrinsic factors in Acute Myeloid Leukemia (AML) generation and persistence has gained interest. Bitter taste receptors (TAS2Rs) are G protein-coupled known for their primary role as a central warning signal to induce aversion toward noxious or harmful substances. Nevertheless, the increasing amount evidence about extra-oral localization suggested wider function sensing microenvironment, also cancer settings. In this study, we found that AML cells express functional...
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasia with a complex polyclonal architecture. Among driver lesions, those involving the
The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF treated ruxolitinib, we investigated incidence and risk factors for BP described outcome according disease characteristics treatment strategy. After a median follow-up from start 3 years (range 0.1-7.6), 65 (11%) transformed during (93.8%) or after treatment. rate was 3.7 per 100 patient-years, comparably primary secondary (PMF/SMF) but significantly lower...
Since low JAK2V617F allele burden (AB) has been detected also in healthy subjects, its clinical interpretation may be challenging patients with chronic myeloproliferative neoplasms (MPNs). We tested 1087 subjects for mutation on suspicion of hematological malignancy. Only 497 (45.7%) were positive. Here we present and laboratory parameters a cohort 35/497 an AB ≤ 3%.Overall, 22/35 (62.9%) received WHO-defined diagnosis MPN 14/35 cases (40%) was supported by bone marrow (BM) histology...
Abstract Epigenetic histone modifiers are key regulators of cell fate decisions in normal and malignant hematopoiesis. Their enzymatic activities particular significance as putative therapeutic targets leukemia. In contrast, less is known about the contextual role which those exercised specifically how different macromolecular complexes configure same activity with distinct molecular cellular consequences. We focus on KAT2A, a lysine acetyltransferase responsible for H3 9 acetylation, we...
Myelofibrosis (MF) and essential thrombocythaemia (ET) are clonal disorders with driver mutations (JAK2, CALR, MPL), chronic inflammation abnormalities in megakaryocyte development platelet activation. The absence of the 3 "driver" identifies triple negative (TN) patients. Ruxolitinib (a JAK1/2 inhibitor) reduces splenomegaly constitutional symptoms MF. However, over 50% patients fail to achieve a response or lose it time (Tefferi & Pardanani, 2015; Vainchenker et al, 2018). Extracellular...
Introduction Extracellular vesicles (EVs) and particles (EPs) represent reliable biomarkers for disease detection. Their role in the inflammatory microenvironment of severe COVID-19 patients is not well determined. Here, we characterized immunophenotype, lipidomic cargo functional activity circulating EPs from (Co-19-EPs) healthy controls (HC-EPs) correlating data with clinical parameters including partial pressure oxygen to fraction inspired ratio (PaO2/FiO2) sequential organ failure...
Abstract Background Myelofibrosis (MF) is a clonal disorder of hemopoietic stem/progenitor cells (HSPCs) with high prevalence in elderly patients and mutations three driver genes ( JAK2 , MPL or CALR ). Around 10–15% are triple-negative (TN) for the display significantly worse survival. Circulating extracellular vesicles (EVs) play role intercellular signaling increased inflammation cancer. To identify biomolecular signature TN patients, we comparatively evaluated circulating HSPCs their...
Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen's safety and activity patients with stable MPNs, no prior thrombotic events JAK2
Acute myeloid leukemia (AML) is an aggressive disease with a high relapse rate. In this study, we map the metabolic profile of CD34